Results 91 to 100 of about 20,878 (216)

Warm Autoimmune Haemolytic Anaemia Management in Asia‐Pacific: A Delphi Panel Expert Consensus and Systematic Literature Review

eJHaem, Volume 6, Issue 6, December 2025.
ABSTRACT Objective This study aimed to assess the burden of warm autoimmune haemolytic anaemia (wAIHA) and treatment practices in the Asia‐Pacific (APAC) region. Methods A systematic literature review (SLR) of observational studies in adult patients with wAIHA was conducted.
Phil Choi, Alberta Hoi, Rong Fu, Jun‐ho Jang, Yok Lam Kwong, Yoshitaka Miyakawa, Chi‐Chiu Mok, Hiroaki Niiro, Yasutaka Ueda, Robert Bagnall, Petya Kodjamanova, Da Eun Ahn, Nakul Saxena, Bryan Wahking, Shin‐Seok Lee   +14 more
wiley   +1 more source

EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells

, 2020
Sanja Nabergoj, Tijana Markovič, Damjan Avsec, Martina Gobec, Helena Podgornik, Žiga Jakopin, Irena Mlinarič‐Raščan   +6 more
openalex   +1 more source

Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment [PDF]

, 2014
Xiaohui Zheng, Ning Ding, Yuqin Song, Lixia Feng, Jun Zhu   +4 more
openalex   +1 more source

Radiation‐Induced Biological Effects: Molecular and Cellular Mechanism, and Applications to Radiation/Nuclear Emergency and Cancer Therapy

MedComm, Volume 6, Issue 12, December 2025.
Radiation‐induced biological effects are an extremely complex and extensive mechanism that involves multiple aspects of physiological activities in organisms. In the medical field, utilizing the damaging effects of radiation to treat tumors is a commonly employed therapeutic approach.
Zhihe Hu, Yan Chen, Shengyi Yang, Shihai Diao, Le Ma, Chunmeng Shi   +5 more
wiley   +1 more source

Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route

Therapeutic Advances in Hematology
Background: Ibrutinib is the only Bruton tyrosine kinase inhibitor (BTKi) with once-daily oral capsule, tablet, and oral suspension formulations approved in the United States across indications of chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Jonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, Michelle Pacia, Heena Mavani, Harisha Atluri, Thomas J. Huemann, Jessica Shelly, Yemin Liu, Shayna Sarosiek   +9 more
doaj   +1 more source

Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Frontiers in Hematology
BackgroundMantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses ...
Catarina Fernandes, Rita Costa e Sousa, Pedro Santos, Cátia Almeida, Adriana Roque, Ana Luísa Pinto, Joaquim Monteiro, Anabela Neves, Maria João Ramos, Rita Coutinho, Rita Coutinho, Rita Coutinho, Filipa Mousinho, Mariana Leal Fernandes, Margarida Badior, Cristina João, Cristina João, Sónia Leocádio, Ana Luísa Tomé, Margarida Carrolo, Sara Dias, Maria Gomes da Silva, João Paulo Fernandes   +22 more
doaj   +1 more source

Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program [PDF]

, 2018
Peter Hillmen, Joris Diels, Nollaig Healy, Wafae Iraqi, J Aschan, Mark Wildgust   +5 more
openalex   +1 more source

Comparación indirecta ajustada de zanubrutinib e ibrutinib en el tratamiento de primera línea de la leucemia linfocítica crónica

, 2023
Francisco Javier Salmerón-Navas, Ester María Barreiro-Fernández, S Fénix-Caballero   +2 more
openalex   +1 more source

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial [PDF]

, 2022
G.A. Amos Burke, Luciana Vinti, Edita Kabíčková, Auke Beishuizen, Nurdan Taçyıldız, Anne Uyttebroeck, Hyoung Jin Kang, Flávio Augusto Vercillo Luisi, Véronique Minard‐Colin, Birgit Burkhardt, Monelle Tamegnon, Steven Sun, Madeliene Curtis, Sanjay Deshpande, Kerri Nottage, Angela Howes, Srimathi Srinivasan, Deepa Bhojwani, Robin E. Norris, Mitchell S. Cairo   +19 more
openalex   +1 more source

Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes

Research
Background: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF).
Yukun Li, Xinmeng Liu, Rong Lin, Xiaodong Peng, Xuesi Wang, Fanchao Meng, Shuqi Jin, Wenhe Lv, Xiaoying Liu, Zhuohang Du, Songnan Wen, Rong Bai, Yanfei Ruan, Hao Zhou, Rongjun Zou, Ribo Tang, Nian Liu   +16 more
doaj   +1 more source